BE1005511A4 - Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspensions injectables les renfermant. - Google Patents

Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspensions injectables les renfermant. Download PDF

Info

Publication number: BE1005511A4
Authority: BE; Belgium
Prior art keywords: radical; carbon atoms; microspheres; sep; hydrogen atom
Prior art date: 1989-11-15

Application number

BE9001062A

Other languages

English (en)

French (fr)

Inventor

Gerard Cohen

Jean-Luc Dubois

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-15

Filing date

1990-11-09

Publication date

1993-08-31

1990-11-09 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1993-08-31 Application granted granted Critical

1993-08-31 Publication of BE1005511A4 publication Critical patent/BE1005511A4/fr

Links

239000004005 microsphere Substances 0.000 title claims abstract description 61
238000000034 method Methods 0.000 title claims abstract description 14
239000000725 suspension Substances 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims abstract description 4
238000002347 injection Methods 0.000 title 1
239000007924 injection Substances 0.000 title 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 51
229920001577 copolymer Polymers 0.000 claims abstract description 32
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 26
150000003431 steroids Chemical class 0.000 claims abstract description 18
230000001833 anti-estrogenic effect Effects 0.000 claims abstract description 16
239000000328 estrogen antagonist Substances 0.000 claims abstract description 16
229940046836 anti-estrogen Drugs 0.000 claims abstract description 7
-1 hydrocarbon radical Chemical class 0.000 claims description 52
125000004432 carbon atom Chemical group C* 0.000 claims description 49
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
150000003254 radicals Chemical class 0.000 claims description 23
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 20
239000002904 solvent Substances 0.000 claims description 12
DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
239000012074 organic phase Substances 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
239000008346 aqueous phase Substances 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 6
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 6
238000003756 stirring Methods 0.000 claims description 6
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 5
239000003995 emulsifying agent Substances 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
125000000304 alkynyl group Chemical group 0.000 claims description 4
125000000732 arylene group Chemical group 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 4
230000008020 evaporation Effects 0.000 claims description 4
150000002576 ketones Chemical group 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
238000005406 washing Methods 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
125000006017 1-propenyl group Chemical group 0.000 claims description 2
239000004215 Carbon black (E152) Substances 0.000 claims description 2
150000000795 D-homosteroids Chemical group 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 2
XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical compound C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 claims description 2
238000010438 heat treatment Methods 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
229930195733 hydrocarbon Natural products 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
RDKRLZMGGDOEPU-UHFFFAOYSA-N n-methyl-8-phenyloctanamide Chemical compound CNC(=O)CCCCCCCC1=CC=CC=C1 RDKRLZMGGDOEPU-UHFFFAOYSA-N 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 claims description 2
239000012071 phase Substances 0.000 claims description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
229920000053 polysorbate 80 Polymers 0.000 claims description 2
235000010413 sodium alginate Nutrition 0.000 claims description 2
239000000661 sodium alginate Substances 0.000 claims description 2
229940005550 sodium alginate Drugs 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
238000011282 treatment Methods 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
208000030499 combat disease Diseases 0.000 description 1
150000004696 coordination complex Chemical class 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BE9001062A 1989-11-15 1990-11-09 Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspensions injectables les renfermant. BE1005511A4 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR898914976A FR2654337B1 (fr)	1989-11-15	1989-11-15	Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.

Publications (1)

Publication Number	Publication Date
BE1005511A4 true BE1005511A4 (fr)	1993-08-31

Family

ID=9387417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE9001062A BE1005511A4 (fr)	1989-11-15	1990-11-09	Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspensions injectables les renfermant.

Country Status (13)

Country	Link
JP (1)	JPH03294229A (de)
AT (1)	AT400298B (de)
BE (1)	BE1005511A4 (de)
CA (1)	CA2029940A1 (de)
CH (1)	CH681691A5 (de)
DE (1)	DE4036425A1 (de)
DK (1)	DK270990A (de)
FR (1)	FR2654337B1 (de)
GB (1)	GB2239798B (de)
IT (1)	IT1242010B (de)
LU (1)	LU87836A1 (de)
NL (1)	NL9002492A (de)
SE (1)	SE9003570L (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA924811B (en) *	1991-06-28	1993-12-29	Endorecherche Inc	Controlled release systems and low dose androgens
HU222501B1 (hu) *	1991-06-28	2003-07-28	Endorecherche Inc.	MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
RU2128055C1 (ru) *	1992-12-07	1999-03-27	Такеда Кемикал Индастриз Лтд.	Фармацевтическая композиция замедленного высвобождения и способ ее получения
ES2105525T3 (es) *	1993-06-24	1997-10-16	Lilly Co Eli	2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
US5910492A (en) *	1995-06-05	1999-06-08	Takeda Chemical Industries, Ltd.	Osteogenic promoting pharmaceutical composition
EP2210585A1 (de)	2009-01-16	2010-07-28	Exelgyn	Pharmazeutische SPRM-Zusammensetzungen, Behandlungsverfahren unter Anwendung dieser

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2070153A1 (de) *	1969-10-23	1971-09-10	Du Pont
FR2537980A1 (fr) *	1982-12-17	1984-06-22	Sandoz Sa	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
GB2160873A (en) *	1984-06-29	1986-01-02	Roussel Uclaf	11B-(4-Aminophenyl) estra-4,9-dienes
EP0196707A1 (de) *	1982-06-11	1986-10-08	Roussel-Uclaf	In Stellung 11 und 17 und gegebenenfalls in Stellung 2 substituierte 19-Nor-Steroide, ihre Herstellung, ihre Anwendung als Arzneimittel, die sie enthaltenden Zusammensetzungen und die erhaltenen Zwischenprodukte

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4293539A (en) *	1979-09-12	1981-10-06	Eli Lilly And Company	Controlled release formulations and method of treatment
US4389330A (en) *	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4530840A (en) *	1982-07-29	1985-07-23	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
ES8502612A1 (es) *	1983-06-15	1985-02-01	Schering Ag	Procedimiento para la preparacion de 13a-alquilgonanos
GB8327256D0 (en) *	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
CA1256638A (en) *	1984-07-06	1989-06-27	Motoaki Tanaka	Polymer and its production
FR2573657B1 (fr) *	1984-11-29	1989-05-12	Roussel Uclaf	Produit comprenant une substance antiprogestomimetique et une substance uterotonique
DE3533175A1 (de) *	1985-09-13	1987-03-19	Schering Ag	Antigestagene zur verschiebung der endometrialen reifung
FR2596395B1 (fr) *	1986-03-26	1989-05-26	Roussel Uclaf	Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4758435A (en) *	1986-08-11	1988-07-19	American Cyanamid Company	Estradiol implant composition and method for preparation
DE3633244A1 (de) *	1986-09-26	1988-03-31	Schering Ag	Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE3733478A1 (de) *	1987-10-01	1989-04-13	Schering Ag	Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) *	1987-10-01	1994-06-08	Schering Aktiengesellschaft	Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3744054A1 (de) *	1987-12-21	1989-06-29	Schering Ag	Verwendung von antigestagenen zur herstellung von arzneimitteln
JP2785023B2 (ja) *	1987-12-30	1998-08-13	ルセル―ユクラフ	１７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JP2670680B2 (ja) *	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法

1989
- 1989-11-15 FR FR898914976A patent/FR2654337B1/fr not_active Expired - Fee Related
1990
- 1990-11-08 LU LU87836A patent/LU87836A1/fr unknown
- 1990-11-09 SE SE9003570A patent/SE9003570L/ not_active Application Discontinuation
- 1990-11-09 BE BE9001062A patent/BE1005511A4/fr not_active IP Right Cessation
- 1990-11-13 IT IT48470A patent/IT1242010B/it active IP Right Grant
- 1990-11-13 DK DK270990A patent/DK270990A/da not_active Application Discontinuation
- 1990-11-14 CH CH3611/90A patent/CH681691A5/fr not_active IP Right Cessation
- 1990-11-14 JP JP2306374A patent/JPH03294229A/ja active Pending
- 1990-11-14 CA CA002029940A patent/CA2029940A1/fr not_active Abandoned
- 1990-11-15 NL NL9002492A patent/NL9002492A/nl not_active Application Discontinuation
- 1990-11-15 GB GB9024862A patent/GB2239798B/en not_active Expired - Fee Related
- 1990-11-15 DE DE4036425A patent/DE4036425A1/de not_active Withdrawn
- 1990-11-15 AT AT0231390A patent/AT400298B/de not_active IP Right Cessation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2070153A1 (de) *	1969-10-23	1971-09-10	Du Pont
EP0196707A1 (de) *	1982-06-11	1986-10-08	Roussel-Uclaf	In Stellung 11 und 17 und gegebenenfalls in Stellung 2 substituierte 19-Nor-Steroide, ihre Herstellung, ihre Anwendung als Arzneimittel, die sie enthaltenden Zusammensetzungen und die erhaltenen Zwischenprodukte
FR2537980A1 (fr) *	1982-12-17	1984-06-22	Sandoz Sa	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
GB2160873A (en) *	1984-06-29	1986-01-02	Roussel Uclaf	11B-(4-Aminophenyl) estra-4,9-dienes

Also Published As

Publication number	Publication date
GB2239798B (en)	1993-10-27
LU87836A1 (fr)	1991-05-07
ATA231390A (de)	1995-04-15
CH681691A5 (de)	1993-05-14
NL9002492A (nl)	1991-06-03
SE9003570L (sv)	1991-05-16
IT1242010B (it)	1994-02-02
IT9048470A0 (it)	1990-11-13
IT9048470A1 (it)	1992-05-13
FR2654337B1 (fr)	1994-08-05
DE4036425A1 (de)	1991-05-16
AT400298B (de)	1995-11-27
DK270990D0 (da)	1990-11-13
GB2239798A (en)	1991-07-17
DK270990A (da)	1991-05-16
JPH03294229A (ja)	1991-12-25
FR2654337A1 (fr)	1991-05-17
SE9003570D0 (sv)	1990-11-09
CA2029940A1 (fr)	1991-05-16
GB9024862D0 (en)	1991-01-02

Legal Events

Date

Code

Title

Description

1999-05-31

RE

Patent lapsed

Owner name: ROUSSEL UCLAF

Effective date: 19981130

Publication	Publication Date	Title
BE1004486A3 (fr)	1992-12-01	Formulations a liberation prolongee de peptides solubles dans l'eau.
US4801739A (en)	1989-01-31	Oligomeric hydroxycarboxylic acid derivatives, their production and use
CA2463358C (fr)	2012-03-13	Microspheres biodegradables a liberation prolongee et leur procede de preparation
WO1991015193A1 (fr)	1991-10-17	Microspheres, leur procede de preparation et leur utilisation
FR2810885A1 (fr)	2002-01-04	Microparticule a liberation soutenue et procede de fabrication
LU88151A1 (fr)	1993-02-15	Composition pour la libération prolongée et contrôlée d'une substance médicamenteurse peptidique et procédé pour sa préparation
BE1005511A4 (fr)	1993-08-31	Utilisation de nouvelles microspheres injectables biodegradables, procede de preparation de ces nouvelles microspheres et suspensions injectables les renfermant.
WO2003004024A1 (en)	2003-01-16	Injectable sustained-release microspheres of huperzine a compounds
KR20200138066A (ko)	2020-12-09	캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법
FR2684101A1 (fr)	1993-05-28	Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
BE1001687A5 (fr)	1990-02-06	Composition a base de polyesters pour la liberation controlee de substances medicamenteuses.
BE898430A (fr)	1984-06-12	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation.
WO2002003957A2 (en)	2002-01-17	Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
CN102652736A (zh)	2012-09-05	一种大豆异黄酮缓释微球的制备方法
EP0151140B1 (de)	1986-12-03	Salz von 2-piperazinopyrimidin, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammenstellungen
FR2801055A1 (fr)	2001-05-18	Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
JPS6341416A (ja)	1988-02-22	鎮痛性ペプチド含有マイクロカプセルの製造法
JP2013538855A (ja)	2013-10-17	低い残留有機溶剤の微粒子を製造するためのエマルション法
CA1202631A (fr)	1986-04-01	Derives de la quinidine, procede de preparation et application en therapeutique
CN1256314C (zh)	2006-05-17	具有降糖降脂活性的非环1，3－二羰基ppar双激活化合物及其药用制剂的制备方法
CN120081800A (zh)	2025-06-03	一种普拉克索月桂酸盐、微球缓释制剂及其制备方法和用途
FR2648814A1 (fr)	1990-12-28	L'alpha (tert-butyl-aminomethyl-3,4-dichlorobenzyl)thioacetamide, son procede de preparation et son application en therapeutique
CN1306530A (zh)	2001-08-01	用于治疗中枢神经系统疾病的帕罗西汀10－樟脑磺酸盐
WO2004016580A2 (fr)	2004-02-26	Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
FR2830448A1 (fr)	2003-04-11	Microspheres biodegradables a liberation prolongee et leur procede de preparation